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Abstract: 
It has been recently reported that bi-allelic mutations in the ERCC4 (FANCQ) gene cause 
Fanconi Anemia (FA) subtype FA-Q. To investigate the possible role of ERCC4 in breast 
and ovarian cancer susceptibility, as occurs with other FA genes, we screened the 11 
coding exons and exon-intron boundaries of ERCC4 in 1573 index cases from high risk 
Spanish familial breast and ovarian cancer pedigrees that had been tested negative for 
BRCA1 and BRCA2 mutations and 854 controls. The frequency of ERCC4 mutation 
carriers does not differ between cases and controls, suggesting that ERCC4 is not a cancer 
susceptibility gene. Interestingly, the prevalence of ERCC4 mutation carriers (1 in 288) is 
similar to that reported for FANCA while there are approximately 100 fold more FA-A 
than FA-Q patients, indicating that most bi-allelic combinations of ERCC4 mutations are 
embryo lethal. Finally, we identified additional bone fide FA ERCC4 mutations 
specifically disrupting interstrand crosslink repair. 
  
The ERCC4 (FANCQ) gene (MIM 133520) encodes for a DNA repair 
endonuclease (XPF) that plays essential roles in nucleotide excision repair (NER) and 
interstrand crosslink repair (ICLR) (Gregg, et al., 2011). Bi-allelic mutations in ERCC4 
have been  linked to Xeroderma Pigmetosum (XP [MIM 278700; 610651; 278720; 
278730; 278740; 278760; 278780; 278750]) (Sijbers, et al., 1996) and progeria (XFE 
[MIM 610965]) (Niedernhofer, et al., 2006) diseases. Very recently, it has been published 
that bi-allelic mutations in the gene are also causative of disease in previously 
unclassified Fanconi Anemia (FA) patients subtype FA-Q and, therefore, the use of 
FANCQ as an alias for ERCC4 was approved by the HUGO Gene Nomenclature 
Committee(Bogliolo, et al., 2013). Individuals harbouring mutations in ERCC4 show high 
variability on their clinical manifestations, ranging from mild XP symptoms (sun 
sensitivity, freckling of the skin and basal or squamous cell carcinomas) to the dramatic 
accelerated aging symptoms of a progeroid syndrome, and finally, as recently shown 
(Bogliolo, et al., 2013) in FA patients, to malformations and progressive bone marrow 
failure. It has been also demonstrated that a balance between NER and ICLR activities 
due to different effects caused by distinct mutations in ERCC4 determined the final 
clinical outcome (Bogliolo, et al., 2013). On the other hand, given that FA-Q patients are 
normal in FANCD2 monoubiquitination, it has been suggested  that mono-allelic 
mutations in ERCC4 could be linked to the breast and ovarian hereditary cancer 
syndrome as it occurs with other FA genes such as BRCA2/FAND1 (Howlett, et al., 
2002), BRIP1/FANCJ (Seal, et al., 2006), PALB2/FANCN (Rahman, et al., 2007) and 
RAD51C/FANCO (Meindl, et al., 2010; Osorio, et al., 2012) (MIM 300514, 610832, 
614082, and 614083, respectively) (Levy-Lahad, 2010). 
 To investigate the possible role of ERCC4 in breast and ovarian cancer susceptibility, we 
screened by DHPLC (Denaturing High Performance Liquid Chromatography) and direct 
sequencing the 11 coding exons and exon-intron boundaries of the ERCC4 gene in 1573 
index cases from high risk Spanish familial breast and ovarian cancer pedigrees that had 
been tested negative for mutations in BRCA1 and BRCA2 and 854 controls without 
personal or familial antecedents of cancer. Criteria for inclusion of cases and controls, 
and methods of screening for mutations in BRCA1/2 have been previously published 
(Romero, et al., 2011; Fernandez-Rodriguez, et al., 2012; Osorio, et al., 2012; Bonache, et 
al., 2013) . We identified five and four unique variants among cases and controls among 
which three and four respectively were considered as putatively deleterious. Missense 
mutations were evaluated using the program CONDEL that predicts the pathogenicity of 
non synonymous variants using a consensus deleteriousness score that combines various 
tools such as SIFT, Polyphen2 and MutationAssessor (http://bg.upf.edu/condel/home). 
Those missense variants predicted to be deleterious by CONDEL were considered as 
predicted to affect protein function and this was studied later by functional analysis; those 
predicted to be neutral were considered as such and not further evaluated (Table 1). 
Regarding cases, one of the mutations found, c.584+1G>A in intron 3, was confirmed to 
cause skipping of exon 3 of the gene and a premature stop codon (PTC) (data not shown). 
The other two mutations, p.Arg150Cys in exon 3 and p.Ser786Phe in exon 11 were later 
functionally investigated. Regarding controls, we identified two different frameshift 
mutations c.540_541delAG in exon 3 (found in two independent controls) and 
c.2291delG in exon 11, both predicted to cause PTCs. Even though this later PTC is very 
C-terminal and could potentially result in a shorter but partially functional protein, this 
mutation results in a truncated XPF protein that lacks the double helix-hairpin-helix 
(HhH2) domain involved in heterodimerization with ERCC1 and DNA binding (de Laat, 
et al., 1998), very similar to a pathogenic ERCC4 mutation (c.2371_2398dup28; 
p.Ile800Thrfs*24) that functionally disrupts NER and ICLR activities (Bogliolo, et al., 
2013). The last deleterious variant found in controls was the missense p.Arg689Ser in 
exon 11  previously found in a FA patient, and demonstrated to cause abnormal nuclease 
activity and to specifically disrupt ICLR (Bogliolo, et al., 2013). No differences were 
found regarding localization of mutations in the gene among cases and controls (Table 1). 
All variants reported have been submitted to the Leiden Open Variation Database 
(LOVD). 
To evaluate the functional impact of the missense variants, we cloned a- HA-tagged WT 
ERCC4 cDNA in a pBABE-puro retroviral vector (Addgene plasmid 14430, kindly 
shared by Dr. LM Martins) in IRES with the GFP cDNA, and the c.448C>T, c.2065C>A 
and c.2357C>T variants were introduced by site directed mutagenesis (Bogliolo, et al., 
2013). The resulting constructs were transduced in NER and ICLR deficient Ercc4 KO 
mouse embryonic fibroblasts (MEFs) and, after puromicin selection, the green cells were 
sorted to achieve a purity of over 98% by FACS (Bogliolo, et al., 2013). Due to the 
bicistronic nature of the IRES construct, we were able to assess the stability of the mutant 
XPF proteins using GFP as a reference, since both proteins are encoded by the same 
mRNA (Pelletier and Sonenberg, 1988). The p.Arg689Ser variant reduced by 40% the 
stability of XPF, while the p.Arg150Cys and p.Ser786Phe variants had no impact on 
protein stability (Fig. 1A and 1B). UVC sensitivity of Xpf KO MEFs was complemented 
with the expression of both p.Arg150Cys- and p.Ser786Phe-XPF (Fig. 1C), and only the 
Xpf KO MEFs expressing  p.Ser786Phe-XPF or p.Arg689Ser showed a FA phenotype in 
terms of mitomycin C (MMC) sensitivity (Fig. 1D), MMC-induced cell cycle arrest at the 
G2/M phase (Fig. 1E) and DEB-induced chromosome fragility (Fig. 1F). These data 
confirms that, resembling p.Arg689Ser, p.Ser786Phe specifically disrupts ICLR and, 
therefore, is a bone-fide FA mutation. Interestingly, both mutations are located in the 
nuclease domain of XPF. Despite a mild MMC sensitivity (Fig. 1D and 1E), Ercc4 KO 
MEFs expressing p.Arg150Cys-XPF did not show DEB-induced chromosome fragility 
(Fig 1F). These data, together with the protein stability and UVC sensitivity data, indicate 
a null impact of the c.448C>T variant on XPF NER functions and a mild effect on ICLR 
activity.  
 
In conclusion, the frequency of Spanish individuals heterozygous for pathogenic 
mutations in the ERCC4 gene is approximately 0,3% and it does not differ between 
familial breast/ovarian cancer patients and  healthy controls (p=0.251), suggesting that 
mono-allelic mutations in ERCC4 are not linked to cancer susceptibility in the general 
population. Similar results were found with SLX4 that, like ERCC4, acts downstream 
FANCD2 monoubiquitination but upstream the homologous recombination step of ICL 
(Fernandez-Rodriguez, et al., 2012). The prevalence of ERCC4 mutation carriers (1 in 
288) is similar to that reported for FANCA. However, there are approximately 100 fold 
more FA-A than FA-Q individuals, suggesting that over 90% of bi-allelic combinations 
of ERCC4 mutations are embryo lethal in humans. All reported XP patients subtype XPF 
world-wide have at least one missense mutation disrupting NER while all missense 
mutations found in 2.427 Spanish individuals have substantial NER activity explaining 
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Legend to figure 
 
Figure 1: Funcional studies of ERCC4 missense variants. (A) Western blot analysis 
showing HA-XPF and GFP expressions in the transduced MEFs as a measure of XPF 
protein stability. XPF levels were quantified with ImageJ software and are expressed as a 
ratio relative to the GFP levels. (B) XPF levels were quantified as in (A) and expressed as 
a percentage of the WT. Mean and SEM of 6 experiments are shown (* p=0.005 t-student 
test). (C) UVC sensitivity of Ercc4 KO MEFs expressing the different alleles of ERCC4. 
Cells were analysed 72 h post irradiation. Data represent means and SD of three 
independent experiments. (D) MMC sensitivity in the same cells as in C. Data represent 
means and SD of two independent experiments. (E) MMC-induced G2/M cell cycle arrest 
in the same cells as in (C). (F) DEB-induced chromosome fragility test arrest in the same 
cells as in (C). Chromatid breaks were scored in 25 metaphase per point. Methods for 
western blot, site-directed mutagenesis, cDNA transduction, antibodies used and the 
experiments presented in D, E and F were performed as reported earlier (Trujillo, et al., 
2012; Bogliolo, et al., 2013).  
 
 
